Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 16/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384577 | 0.93 | BCL2 (0.54) | BCL2BCL2L1 | |
| SCHEMBL19424649 | 0.79 | BCL2L1 (0.45) | BCL2BCL2L1 | |
| SCHEMBL2384452 | 0.75 | SRD5A2 (0.41) | BCL2BCL2L1 | |
| SCHEMBL2389444 | 0.72 | BCL2L1 (0.53) | BCL2BCL2L1 | |
| SCHEMBL17004390 | 0.72 | BCL2L1 (0.53) | BCL2BCL2L1 | |
| SCHEMBL2389447 | 0.72 | BCL2L1 (0.53) | BCL2BCL2L1 | |
| SCHEMBL2388665 | 0.72 | BCL2 (0.50) | BCL2BCL2L1 | |
| SCHEMBL2388106 | 0.71 | BCL2L1 (0.52) | BCL2BCL2L1 | |
| SCHEMBL2390310 | 0.71 | BCL2 (0.46) | BCL2BCL2L1 | |
| SCHEMBL19424606 | 0.70 | BCL2L1 (0.38) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2 520/4885BCL2L1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.